Navigation Links
Antibiotic Resistance 2013: The Antibiotics Development Pipeline and Strategies to Combat Antibiotic Resistance
Date:4/2/2013

DUBLIN, Ireland, April 2, 2013 /PRNewswire/ --

Research and Markets has announced the addition of the "Antibiotic Resistance 2013: The Antibiotics Development Pipeline and Strategies to Combat Antibiotic Resistance" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

This report gives a comprehensive overview of global antibiotic resistance, the antibiotics pipeline and new strategies to target resistance mechanisms. It identifies 109 antibiotics in the development pipeline, approximately 70% of which are in early development (Preclinical and Phase 1). In contrast, there are just 9 candidates at Phase 3, while there are 31 at Phase 2. These developments are being progressed by 66 companies, of which nine (14%) are major international corporations and 57 (86%) are Small/Medium Sized Enterprises (SMEs).

While antibiotics are effective for the majority of infections, increasing resistance in some pathogens threatens to undermine the few remaining drugs that are still effective against them. This is evident in the case of Klebsiella pneumoniae. Since 2005, there has been a significant decrease of susceptibility to carbapenems in invasive Klebsiella pneumoniae, causing concerns due to the lack of therapeutic options for treating these infections.

Antibiotic resistance is a long-evolved trait in prokaryotes. The extensive capabilities of the resistome, together with the ability of bacteria to establish new mutant variants in response to man-made antibiotics, suggest that antibiotic resistance will remain an ever-present threat. It is therefore not so much a question of whether a pathogen will become resistant to an antibiotic, but when. However, the development of new drugs and targeting mechanisms provide an opportunity to reset the clock on resistance levels in particular pathogens.

In the last decade, the capacity to target pathogens has also been undermined by a lack of innovation, which has seen a 60% fall in the numbers of new approvals and few novel molecules. However, as this report has shown, this trend is changing. Today, there are more than 100 candidate antibiotics in development, of which half are in the clinical pipeline. While there are several promising candidates at Phase 3 which offer hope of new approvals in the coming years, Phase 2 developments are now substantial, suggesting the emergence of a new era in the types of antibiotics and the strategies that will be available to target pathogens in the future.

Key Topics Covered:

Executive Summary

Chapter 1 Introduction

1.1 Antibiotic Resistance
1.2 Resistance Mechanisms
1.3 The Resistome
1.4 Pathogenomics
1.5 Strategies and Targets
1.6 The Cost of Antibiotic Resistance
1.7 Global Surveillance
1.8 This Report

Chapter 2 Antibiotic Resistance, Global Trends

2.1 Antibiotic Resistance
2.2 Europe
2.2.1 Carbapenem-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa (2005 to 2010)
2.2.2 Escherichia coli
2.2.3 Streptococcus pneumoniae
2.2.4 Staphylococcus aureus
2.2.5 Enterococcus faecalis
2.2.6 Klebsiella pneumoniae
2.2.7 Pseudomonas aeruginosa
2.3 Other Countries
2.4 China
2.5 USA
2.6 Kuwait
2.7 Discussion

Chapter 3 Marketed Antibiotics

3.1 Marketed Antibiotics
3.2 Mechanisms
3.3 Companies
3.4 Sulphonamides
3.5 Beta Lactams (penicillins, cephalosporins, carbapenems, monobactams)
3.6 Aminoglycosides
3.7 Tetracyclines
3.8 Quinolones/Fluoroquinolones
3.9 Macrolides
3.10 Combinations
3.11 Folate antagonists
3.12 Mycobacterials
3.13 Glycopeptides
3.14 Others
3.15 Discussion

Chapter 4 Pipeline Antibiotics

4.1 Pipeline Antibiotics
4.2 Companies
4.3 Phase 3
4.4 Phase 2
4.5 Phase 1
4.6 Preclinical
4.7 Discussion

Chapter 5 Discussion

5.1 Background
5.2 Mechanisms
5.3 Multiple Activities
5.4 Marketed Antibiotics
5.5 Antibiotics Pipeline
5.6 Circumventing Resistance
5.7 Resistance Mutations
5.8 Virulence
5.9 Conclusions


For more information visit Antibiotic Resistance 2013: The Antibiotics Development Pipeline and Strategies to Combat Antibiotic Resistance

Research and Markets
Laura Wood , Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.



'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Stater Bros. Super Rx Pharmacies To Offer Free Antibiotics
2. Mom Was Right: Topical Antibiotics Help Boo-Boos Heal Better
3. Golden Seeds Invests In DxUpClose, Disruptive Technology That Performs An Antibiotic Sensitivity Test At The Patients Bedside In Less Than An Hour
4. Antibiotics and Biotechnology Take Center Stage at Food Dialogues Event
5. TaiGen Biotechnology Out-Licensed China Rights of Novel Antibiotic, Nemonoxacin, to Zhejiang Medicine
6. Kill the Germs, Spare the Ears: Study Shows How to Create Effective Antibiotics That Dont Damage Hearing
7. Diabecline Antibiotic Receives Edison Award for Best New Pharmaceutical Product
8. Abattis Participates In Project On A Whole Plant Therapeutic For Treating Malaria And Other Diseases And Reducing Drug Resistance
9. CBIS Releases Corporate Operational Guidance for 2013 as the Company Reorganizes to better meet the Growing Global Crisis Associated with Anti-Retroviral Drug Resistance among People with AIDS, as well as the Increasing Need for Patient Friendly Ski
10. Countdown to MD&M West 2013: Eleven Days until the Most Comprehensive MedTech Conference in the Nation
11. The Indian Pharmaceutical Industry 2013: Coming of Age in a Global Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... June 23, 2016  In a startling report released today, ... residents by lacking a comprehensive, proven plan to eliminate prescription opioid ... ranking of how states are tackling the worst drug crisis in ... states – Kentucky , New Mexico ... . Of the 28 failing states, three – ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
Breaking Medicine News(10 mins):